Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer

BACKGROUND: The adjuvant short course 9-week trastuzumab combination therapy for human epidermal receptor 2 positive breast cancer patients may often be considered as a cost-effective and safe option and has important implications for the Indian subcontinent as well as other developing countries. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hingmire, Sachin S., Sambhus, Mahesh B., Kelkar, Dhananjay S., Joshi, Sujit, Parikh, Purvish M., Bharath, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
ORIGINAL ARTICLE: Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506806/
https://www.ncbi.nlm.nih.gov/pubmed/28702403
http://dx.doi.org/10.4103/sajc.sajc_68_17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506806/
https://www.ncbi.nlm.nih.gov/pubmed/28702403
http://dx.doi.org/10.4103/sajc.sajc_68_17

Ejemplares similares